| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-11-03 | NBE Therapeutics (Switzerland) | CHF 20 million (€ 18.5 million) | series B financing round | PPF Group (Czech Republic) Boehringer Ingelheim Venture Fund (BIVF) (Germany) existing private investors and a new private investor | Series B financing round | |
| 2016-10-25 | eHealth Ventures (Israel) | financing round | Amgen (USA - CA) Maccabi Healthcare Services (Israel) Medison Pharma (Israel) | Financing round | ||
| 2016-10-18 | Mavalon Therapeutics (UK) | up to € 9 million | financing round | Medicxi Ventures (UK - Switzerland) | Neurodegenerative diseases | Financing round |
| 2016-10-12 | Immunomedics (USA - NJ) | $30 million | private placement | Cancer - Oncology | Private placement | |
| 2016-10-07 | Newron Pharmaceuticals (Italy) | CHF 26.1 million (€ 23.9 million) | private placement | CNS diseases | Private placement | |
| 2016-10-06 | Genfit (France) | € 33.9 million | private placement | Metabolic diseases - Liver diseases - Hepatic diseases | Private placement | |
| 2016-10-06 | PDC*line Pharma (France) | €4 million | financing round, loan, grant | Meusinvest (Belgium) Spinventure (Belgium) the Financière Spin-off Luxembourgeoise/INVESTSUD Group (Belgium), international business angels including Serge Goblet (Tolefi), Baudouin Jolly, Françoise Jolly-de Vaucleroy, Parness SA, Jean-Paul Prieels (former senior vice president of R&D at GSK Vaccines) and Riccardo Cortese (former CEO of Okairos and current CEO of Nouscom) | Cancer - Oncology | Fundraising |
| 2016-10-05 | Scynexis (USA - NJ) | $ 15 million | loan | Solar Capital (USA - CA) | Infectious diseases | Loan |
| 2016-10-05 | Probiodrug (Germany) | € 14.9 million | capital increase | Neurodegenerative diseases | Capital increase | |
| 2016-10-04 | SkylineDx (USA - CA - The Netherlands) Erasmus MC (The Netherlands) Myeloma Patients Europe (Belgium), University of Turin (Italy) the Institute for Medical Technology Assessment (The Netherlands) | multi-million € | grant | European Commission’s Horizon 2020 programme | Cancer - Oncology - Diagnostic | Grant |
| 2016-10-04 | Oxford Immunotec (UK) | $40 million (€35.7 million) | credit line and loan | Midcap Financial (USA - MD) | Diagnostic | Loan |
| 2016-10-04 | NewLink Genetics (USA - IO) | $24.8 million | grant | Biomedical Advanced Research and Development Authority (USA) | Infectious diseases | Grant |
| 2016-10-03 | Carrick Therapeutics (Ireland) | $95 million (€84.7 million) | financing round | ARCH Venture Partners (USA - IL) Cambridge Enterprise Seed Funds (UK) Cambridge Innovation Capital (UK) Evotec (Germany) Google Ventures (USA - CA) Lightstone Ventures (USA - CA) Woodford Investment Management (UK) | Cancer - Oncology | Financing round |
| 2016-10-03 | Array BioPharma (USA - CO) | $132.25 million (€ 117.9 million) | private placement | Cancer - Oncology | Private placement | |
| 2016-10-03 | Array BioPharma (USA - CO) | $132.25 million | private placement | Cancer - Oncology | Private placement | |
| 2016-10-03 | Emmaus Life Sciences (USA) | $20 million | private placement | KPM Tech (Republic of Korea) Hanil Vacuum (Republic of Korea) | Rare diseases - Gastrointestinal diseases | Private placement |
| 2016-09-30 | Onxeo (France) | €12.5 million | capital increase | Cancer - Oncology - Rare diseases | Capital increase | |
| 2016-09-26 | Oryzon Genomics (Spain) | € 10.5 million + € 5.3 million | loan | undisclosed Spanish commercial banks | Cancer - Oncology - Neurodegenerative diseases | Loan |
| 2016-09-23 | Sarepta Therapeutics (USA - MA) | up to $225 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2016-09-23 | AC Immune (Switzerland) | $57.8 million | IPO | Neurological diseases - CNS diseases | IPO |
